Activity of pradimicin BMS-181184 against Aspergillus spp

International Journal of Antimicrobial Agents

Volumn 12, Issue 3, 1999, Pages 267-269

  Oakley, Karen L ^a   Moore, Caroline B ^a   Denning, David W ^a,b,c  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antifungal; Aspergillus spp; Pradimicin; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; BMS 181184; ITRACONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTHRACYCLINES; ANTIBIOTICS, ANTIFUNGAL; ANTIBIOTICS, ANTINEOPLASTIC; ASPERGILLUS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

EID: 0032769125     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00072-2     Document Type: Article

References (13)

1. Revankar S, Patterson TF. Aspergillus and Candida infections in bone marrow transplantation: progress and controversies. Infect Dis Clin Prac 1997;6:506-12.
2. Working Party of the British Society for Antimicrobial Chemotherapy. Therapy of deep fungal infection in haematological malignancy. J Antimicrob Chemother 1997;40:779-788.
3. Denning DW. Diagnosis and management of invasive aspergillosis. In: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Diseases. Boston, MA: Blackwell, 1996:277-300.
4. Denning DW, Hostetler JS, Kauffman CA, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:35-144.
5. Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother 1997;40:753-64.
6. Walsh TJ, Giri N. Pradimicins: a novel class of broad-spectrum antifungal compounds. Eur J Clin Microbiol Infect Dis 1997;16:93-7.
7. Wardle H, Law D, Denning DW. In-vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida spp. Antimicrob Agents Chemother 1996;40:2229-31.
8. Karlowsky JA, Zhanel GG, Balko TB, Zelenitsky SA, Kabani AM, Hoban DJ. In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species. Diagn Microbiol Infect Dis 1997;28:179-82.
9. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE. In-vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 1995;39:295-300.
10. Gonzalez CE, Groll AH, Giri N, Shetty D, Al-Mohsen I, Sein T, Feuerstein E, Bacher J, Piscitelli S, Walsh TJ. Antifungal activity of pradimicin derivative BMS 181184 in the tratment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;9:2399-2404.
11. Groll AH, Sein T, Petraitis V, Petraitiene R, Callender D, Gonzalez CE, Giri N, Bacher J, Piscitelli S, Walsh TJ. Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits., Antimicrob Agents Chemother 1998;10:2700-2705.
12. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992;15:21-34.
13. Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother 1997;35:139-43.